Estonia

Estonia does not operate a national population-level dementia screening program. Case-finding is primarily clinically driven, occurring in primary care and escalating to specialist assessment when symptoms, functional decline, or family concern justify referral. Neuropsychological assessment is a standard component of specialist evaluation and is particularly prominent in the private sector, where structured cognitive testing is marketed as a stand-alone or bundled service. In public specialist settings, cognitive testing is typically combined with clinical examination and collateral history rather than used in isolation.

Both the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are fully accessible in Estonian, facilitating accurate cognitive screening within the country’s healthcare system. To ensure linguistic and cultural precision, the MMSE offers both a standard Estonian version and a specialized Russian for Estonia translation to accommodate the region’s diverse population. Similarly, the MoCA includes Estonian among its extensive list of official language options available via the MoCA Cognition portal. By providing these validated translations, both assessments allow Estonian clinicians to effectively identify mild cognitive impairment and dementia while minimizing the risk of diagnostic errors caused by language barriers.

Structural neuroimaging is an established component of dementia assessment in Estonia. Computed tomography (CT) and magnetic resonance imaging (MRI) are available through both public hospitals and private diagnostic providers, and are routinely used by neurologists and psychiatrists to exclude secondary causes of cognitive impairment and to support differential diagnosis. Access to CT is generally more readily available, whereas MRI may involve longer waiting times, with regional variation in access reflecting differences in imaging capacity and service provision. Patients also have the option of obtaining MRI examinations through private providers on a self-pay basis, although most outpatient imaging services are delivered by providers contracted with the Estonian Health Insurance Fund.

Advanced molecular imaging is much more limited. Positron emission tomography (PET) imaging (including FDG-PET or amyloid PET) is not described as a standard, publicly funded component of routine dementia diagnosis in Estonia. Where amyloid PET is available, it is typically accessed following assessment by a dementia specialist and reserved for carefully selected patients in whom diagnostic uncertainty persists after a comprehensive clinical evaluation.4 Consequently, PET plays a marginal role in everyday diagnostic practice compared with CT and MRI, reinforcing a model centered on structural imaging combined with clinical and cognitive assessment.

Estonia is a leader in population-scale genetics, with national initiatives like the Estonian Genome Project offering widespread DNA data for personalized medicine, including dementia risk, through large biobanks and linking data to health records for healthcare providers.

While large national programs exist, individual genetic testing for dementia risk involves private laboratories like Celvia, specialized genetics clinics at Tartu University Hospital, or direct-to-consumer options, often requiring genetic counseling to interpret results for conditions like Alzheimer’s disease risk genes. However, genetic testing is not part of routine dementia diagnosis in Estonia. Testing for monogenic or familial Alzheimer’s disease (early-onset presentations) may be considered in highly selected cases, typically following specialist referral and genetic counseling. For the vast majority of people living with late-onset dementia, genetic testing, including apolipoprotein E (APOE) genotyping, is not routinely offered or publicly funded as part of clinical care, reflecting a service model that prioritizes clinical evaluation, cognitive testing, and structural imaging over predictive or risk-based genetic approaches.

In 2018 Estonia has launched a state-sponsored genetic testing and counseling service that aims to make genomic information a routine part of healthcare, beginning with 100,000 residents and potentially expanding to the entire population. Built on the country’s long-standing biobank program and delivered through family doctors, the initiative emphasizes prevention, lifestyle adaptation, and professional genetic counseling, reducing the risks of misinterpretation common with direct-to-consumer tests. Estonia’s approach integrates genetics directly into primary care while protecting individual data rights under the Human Genes Research Act, which grants donors control over how their genetic data are used. By embedding genomic testing within a national healthcare framework and strong digital governance, Estonia positions itself as a potential model for how population-scale genetics can support personalized, preventive medicine.

The publicly described dementia-care model in Estonia does not include routine biomarker testing, such as cerebrospinal fluid (CSF) analysis or emerging blood-based biomarkers, as a standard diagnostic step. Where available, their use is guided by specialist neurologists and reserved for selected patients in whom diagnostic uncertainty persists after standard clinical assessment, in line with European recommendations. Blood-based biomarkers remain non-standard and non-routine in clinical care. While Estonia has strong biomedical and digital health infrastructure, there is no evidence that plasma biomarkers for Alzheimer’s disease are deployed at scale within the publicly funded diagnostic pathway.

Estonia does not frame dementia care around a single, branded national “memory clinic network.” Instead, specialist dementia services are embedded within neurology and psychiatry departments, primarily in regional and tertiary hospitals. Within this structure, memory-focused outpatient services operate as part of broader neurology clinics, rather than as stand-alone institutions. A clear example is the Tartu University Hospital, whose neurology outpatient services explicitly include a memory clinic function, integrating cognitive assessment, imaging review, and longitudinal follow-up within a tertiary-care setting. This hospital-anchored model means that dementia expertise is concentrated in larger centers, with smaller regions relying on referral and coordination rather than locally autonomous memory units. As a result, access to specialized dementia assessment depends not only on clinical need but also on regional service capacity and referral flows.

A distinctive feature of the Estonian model is the Dementia Competence Centre (DCC), which operates not as a clinical provider but as a national competence and coordination structure. The DCC was initiated by the Ministry of Social Affairs and is operationally linked to the EHIF. Its mandate is horizontal rather than vertical: supporting regions through collaboration networks, standardization of practice, professional training, and system navigation, rather than delivering diagnostics or treatment directly. This reflects a policy choice to strengthen dementia capacity across existing services instead of building a parallel clinical infrastructure.

The cost of dementia treatment in Estonia reflects the broader mixed-financing structure of the health system. Core medical services, such as GP care, specialist consultations, hospital-based diagnostics, and medically indicated follow-up, are covered for insured individuals through the EHIF. At the same time, out-of-pocket expenditure remains a meaningful component of care. People typically contribute through medication co-payments shaped by reimbursement ceilings and reference pricing rules, while many families also incur direct costs when turning to private providers in order to shorten waiting times for consultations, imaging, or neuropsychological testing. Additional financial pressure arises from non-medical support needs, including aspects of daily care and assistance that fall outside the strictly medical benefits basket. As a result, although Estonia offers broad formal coverage for dementia care, households frequently encounter financial strain at the margins of access and speed, most notably during the diagnostic phase, when the incentives to use private pathways are strongest.

Carer support represents one of the strongest and most distinctive components of Estonia’s dementia response. The DCC functions as a national support hub, providing free-of-charge services that include support groups, counselling, training materials, and an information/trust line. Importantly, DCC materials emphasize nationwide reach, combining on-site activities with virtual access, which partially compensates for regional disparities in specialist medical capacity. Civil society involvement reinforces this layer. MTÜ Elu Dementsusega (Living with Dementia), a participant in Alzheimer’s Disease International (ADI)’s Membership Development Programme, is identified as a key partner within the DCC framework. This collaboration links grassroots advocacy, lived-experience perspectives, and international best practice with Estonia’s institutional support model. Together, the DCC-NGO ecosystem positions caregiver support and system navigation as core policy priorities, even in the absence of a large, dedicated clinical dementia infrastructure. This emphasis reflects an understanding that, in a small health system with limited specialist capacity, coordination, education, and carer resilience are essential to overall dementia-care performance.

Estonia does not currently have a formal national dementia strategy or stand-alone Alzheimer’s disease plan. This is consistently reflected in comparative European policy tracking, including Alzheimer Europe’s national dementia strategies profiles, which list Estonia among countries where dementia is not governed through a dedicated, comprehensive policy framework. Instead, dementia is addressed indirectly through general health system organization, neurology and psychiatry services, ageing-related social policy, and insurance coverage rules administered by the national health insurer. In practical terms, this means there are no nationally endorsed targets for early diagnosis rates, memory clinic coverage, biomarker use, workforce planning specific to dementia, or national monitoring instruments such as a dementia registry. Dementia policy therefore sits at the intersection of health care delivery and social support rather than being articulated as a discrete strategic priority.

Estonia’s Mental Health Action Plan 2023-2026, developed by the Ministry of Social Affairs, sets strategic directions to improve mental health outcomes by strengthening promotion, prevention, community support and access to services, aligning with World Health Organization (WHO) principles of universal coverage, rights-based care and life-course approaches. It focuses on building monitoring systems, expanding community and primary care services, clarifying care pathways and boosting crisis and psychosocial support, particularly after mental health impacts seen during the COVID-19 pandemic. However, the Plan does not specifically address dementia or Alzheimer’s disease as discrete policy priorities. While older adults and life course mental health are mentioned in broader terms, there is no dedicated dementia strategy or action line that targets diagnosis, long-term neurocognitive conditions, caregiving support for dementia, or integration of neurological care pathways within the mental health framework, gaps that leave dementia largely absent from formal mental health policy despite its significant public health impact.

One of Estonia’s most significant scientific innovations relevant to dementia research is the Estonian Biobank at the University of Tartu. The biobank contains genomic and longitudinal health data from more than 210,000 participants, representing approximately 20% of Estonia’s adult population, making it one of the largest population-based biobanks worldwide. This resource supports research into Alzheimer’s disease and other neurodegenerative disorders by enabling studies on genetic risk prediction, biomarker discovery, disease mechanisms, and precision medicine. The integration of genomic data with nationwide electronic health records further facilitates large-scale epidemiological and translational research aimed at improving early detection and personalized treatment strategies.

Estonia is an active member of the Biobanking and BioMolecular Resources Research Infrastructure–European Research Infrastructure Consortium (BBMRI-ERIC) through the Estonian Biobank. This provides researchers with access to international biobanking infrastructure, harmonized biological samples, and collaborative research networks that support studies on Alzheimer’s disease, biomarkers, and neurodegeneration. Participation in BBMRI-ERIC facilitates multinational translational research and accelerates biomarker validation across Europe.
One article done by Tervise Arengu Institute compares dementia care in Estonia and Scotland to explore how person-centred, compassionate approaches could inspire change in the Estonian context. It argues that dementia care is shaped not only by services and policies but also by language, culture, and social attitudes. While Estonia lacks a formal national dementia strategy and remains characterised by fragmented health and social care systems, strong familial responsibility, and lingering stigma, reinforced by medicalised and often dehumanising language, important progress has emerged through grassroots initiatives such as the DCC and the NGO Elu Dementsusega. In contrast, Scotland has pursued a rights-based, person-centred model anchored in national strategy, integrated care, professional training frameworks, and deliberate language reform. Reflections from an Estonian delegation visit to Scotland highlight both the inspiration and the complexity of adapting these models across different cultural and institutional settings. The article concludes that meaningful reform in Estonia will require not simple policy transfer but culturally sensitive co-creation, combining legal and systemic improvements with shifts in discourse, training, community engagement, and recognition of carers, so that people living with dementia are treated as full citizens rather than defined by diagnosis.